Literature DB >> 8450256

Surface antimicrobial activity of heparin-bonded and antiseptic-impregnated vascular catheters.

L A Mermel1, S M Stolz, D G Maki.   

Abstract

Most Swan-Ganz pulmonary artery catheters have heparin bonded to the surface with benzalkonium chloride, a cationic surfactant, to reduce thrombosis. Since benzalkonium is bactericidal, the antimicrobial activity of heparin-bonded pulmonary artery catheters was investigated in an in vitro assay. Each catheter exhibited activity against a wide variety of potential microbial pathogens, including Candida albicans. The magnitude of activity against individual organisms correlated strongly with their in vitro susceptibility to benzalkonium chloride (r = .94, P < .002). A chlorhexidine-silver sulfadiazine-impregnated catheter exhibited even greater activity than the heparin-bonded catheters (P = .01). When exposed to serum for 24 h, heparin-bonded catheters lost > or = 50% of their antimicrobial activity, whereas the activity of the chlorhexidine-silver sulfadiazine-impregnated catheter was minimally affected. The fortuitous surface antimicrobial activity of heparin-bonded catheters may account for the low incidence of catheter-related bacteremia (mean, 1.0%) compared with Swan-Ganz catheters of the same materials but not coated with benzalkonium-heparin (mean, 2.8%).

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8450256     DOI: 10.1093/infdis/167.4.920

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  15 in total

Review 1.  Prevention of infections caused by central venous catheters--established and novel measures.

Authors:  A Bach
Journal:  Infection       Date:  1999       Impact factor: 3.553

2.  The Erlanger silver catheter: in vitro results for antimicrobial activity.

Authors:  T Bechert; M Böswald; S Lugauer; A Regenfus; J Greil; J P Guggenbichler
Journal:  Infection       Date:  1999       Impact factor: 3.553

3.  Durability of anti-infective effect of long-term silicone sheath catheters impregnated with antimicrobial agents.

Authors:  R K Tcholakian; I I Raad
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

4.  Guidelines for the prevention of intravascular catheter-related infections.

Authors:  Naomi P O'Grady; Mary Alexander; Lillian A Burns; E Patchen Dellinger; Jeffrey Garland; Stephen O Heard; Pamela A Lipsett; Henry Masur; Leonard A Mermel; Michele L Pearson; Issam I Raad; Adrienne G Randolph; Mark E Rupp; Sanjay Saint
Journal:  Clin Infect Dis       Date:  2011-04-01       Impact factor: 9.079

5.  Impact of chlorhexidine-silver sulfadiazine-impregnated central venous catheters on in vitro quantitation of catheter-associated bacteria.

Authors:  A Bach
Journal:  J Clin Microbiol       Date:  1996-10       Impact factor: 5.948

Review 6.  Umbilical artery catheters in the newborn: effects of catheter materials.

Authors:  K J Barrington
Journal:  Cochrane Database Syst Rev       Date:  2000

7.  Eradication of biofilm-forming Staphylococcus epidermidis (RP62A) by a combination of sodium salicylate and vancomycin.

Authors:  R E Polonio; L A Mermel; G E Paquette; J F Sperry
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

8.  Biodegradable polymer releasing antibiotic developed for drainage catheter of cerebrospinal fluid: in vitro results.

Authors:  Song Yup Han; Soo Han Yoon; Ki Hong Cho; Han Jin Cho; Jeong Ho An; Young Sin Ra
Journal:  J Korean Med Sci       Date:  2005-04       Impact factor: 2.153

9.  Evaluation of a triple-lumen central venous heparin-coated catheter versus a catheter coated with chlorhexidine and silver sulfadiazine in critically ill patients.

Authors:  M N Carrasco; A Bueno; C de las Cuevas; S Jimenez; I Salinas; A Sartorius; T Recio; M Generelo; F Ruiz-Ocaña
Journal:  Intensive Care Med       Date:  2004-01-13       Impact factor: 17.440

10.  Noninvasive ventilation for patients near the end of life: what do we know and what do we need to know?

Authors:  William J Ehlenbach; J Randall Curtis
Journal:  Crit Care Med       Date:  2008-03       Impact factor: 7.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.